Ostarine (MK-2866) and LGD-4033 (Ligandrol) are the two most extensively characterised selective androgen receptor modulators (SARMs) in the published scientific literature. Both were developed as investigational drugs targeting muscle wasting and bone density loss, both have completed Phase I and Phase II clinical trials, and both are widely used as reference compounds in androgen receptor research. Despite their shared mechanistic class, they differ significantly in receptor binding affinity, tissue selectivity ratios, pharmacokinetic profiles, and the depth of clinical data available.

This comparison is intended for researchers selecting between these compounds for laboratory or pre-clinical work. Neither compound is approved for human use by the TGA or equivalent regulatory bodies.

Development Background

MK-2866 (Ostarine / Enobosarm) was developed by GTx, Inc. as part of a programme to identify non-steroidal AR ligands for treating cancer cachexia, muscle wasting, and osteoporosis. It was the first SARM to complete Phase II clinical trials — the ENOBOSARM-1 and ENOBOSARM-2 trials in non-small cell lung cancer patients — and has the most comprehensive published dataset of any compound in its class.

LGD-4033 (Ligandrol / VK5211) was developed by Ligand Pharmaceuticals and licensed to Viking Therapeutics. Designed as a more potent AR agonist with higher binding affinity as a primary design goal. Phase I dose-escalation studies in healthy volunteers were completed, and Phase II trials (VK5211 in hip fracture recovery) have been conducted. Its clinical dataset is less extensive than MK-2866’s but includes robust human pharmacokinetic data.

Structural Class

MK-2866 belongs to the arylpropionamide class; LGD-4033 belongs to the tetrahydroquinoline class. These structural differences produce distinct receptor binding geometries, different AR conformational changes upon binding, and consequently different tissue selectivity profiles — the structural basis for the pharmacological differences described below.

Androgen Receptor Binding Affinity

Compound	AR Binding Ki	Relative to DHT
DHT (reference)	~0.1 nM	1.0× (reference)
LGD-4033	~1.0 nM	~0.1× DHT
MK-2866	~3.8 nM	~0.026× DHT
Testosterone	~1–3 nM	~0.05–0.1× DHT

LGD-4033 binds the AR with approximately 3.8-fold higher affinity than MK-2866 (Ki ~1.0 nM vs ~3.8 nM). This translates to greater receptor occupancy at equivalent molar concentrations and contributes to LGD-4033’s more potent anabolic effects per mole in pre-clinical models.

Tissue Selectivity: Anabolic-to-Androgenic Ratio

In the orchidectomised rat model (standard pre-clinical selectivity assessment):

MK-2866: Levator ani ED50 = 0.03 mg/day; Prostate ED50 = 0.12 mg/day → A:A ratio ~4:1

LGD-4033: Levator ani ED50 = ~0.006–0.010 mg/day; Prostate ED50 = ~0.021 mg/day → A:A ratio ~2–3:1

LGD-4033 is more potent in absolute terms (lower ED50 in both tissues), but MK-2866’s A:A selectivity ratio is higher. For research where androgenic side effects are a confounder (prostate stimulation in animal models), MK-2866’s higher selectivity ratio may be preferable. For research requiring maximum anabolic stimulus per dose, LGD-4033’s higher potency is advantageous.

Pharmacokinetics: Direct Comparison

Parameter	MK-2866 (Ostarine)	LGD-4033 (Ligandrol)
Human t½ (oral)	24–36 hours	24–36 hours
Rat t½ (IV)	~6 hours	~5 hours
Oral bioavailability	>80% (estimated)	>80% (estimated)
Linear kinetics	Yes (Phase I confirmed)	Yes (Phase I confirmed)
Steady-state (daily)	~5–7 days	~5–7 days

The pharmacokinetic profiles are strikingly similar in humans — both exhibit ~24–36 hour half-lives, high oral bioavailability, and linear kinetics. For comparative research protocols, dosing intervals and washout periods can be kept consistent between compounds, simplifying experimental design.

Clinical Data Comparison

MK-2866 has the larger clinical dataset: Phase II ENOBOSARM trials at 3 mg/day for 116 days in cancer patients produced statistically significant lean body mass gains and functional improvements vs placebo. Adverse event profile was favourable. This is the longest treatment duration and largest clinical population of any SARM studied.

LGD-4033 Phase I (1 mg/day × 21 days in healthy volunteers) showed statistically significant lean body mass increases even at the lowest dose — demonstrating high potency. Dose-dependent HPG axis suppression (testosterone and SHBG reduction) was observed, returning to baseline within 5 weeks. Phase II (VK5211, hip fracture recovery, 2 mg/day × 12 weeks) showed lean body mass and strength improvements.

HPG Axis Suppression

Both compounds suppress the hypothalamic-pituitary-gonadal axis, but LGD-4033 produces more pronounced suppression per milligram. At 1 mg/day in Phase I, LGD-4033 produced measurable testosterone and SHBG reduction. MK-2866 at 3 mg/day in Phase II produced modest HPG effects, less pronounced than testosterone equivalents.

For research requiring minimal HPG interference, MK-2866’s lower suppression per anabolic dose is preferable. For HPG feedback mechanism research via SARM-mediated AR activation, LGD-4033’s more potent suppression provides a cleaner signal.

Research Application Guide

Research Application	Preferred Compound	Rationale
AR binding assays (reference standard)	MK-2866	Largest published comparative dataset
Maximum anabolic stimulus	LGD-4033	~4× higher AR affinity; lower ED50
Tissue selectivity studies	MK-2866	Higher A:A ratio (~4:1 vs ~2–3:1)
HPG axis suppression modelling	LGD-4033	More potent HPG suppression at lower doses
Long-duration protocols	MK-2866	116-day clinical data; best-characterised long-term profile

Summary

• Binding affinity: LGD-4033 binds AR ~4× more tightly than MK-2866
• Potency: LGD-4033 is more potent (lower ED50) in both anabolic and androgenic tissue
• Selectivity ratio: MK-2866 shows higher anabolic-to-androgenic selectivity (~4:1 vs ~2–3:1)
• Pharmacokinetics: Nearly identical — both ~24–36 hour human half-life
• Clinical data: MK-2866 has a substantially larger dataset (116-day Phase II)
• HPG suppression: LGD-4033 produces greater suppression per milligram

Ostarine Australia supplies pharmaceutical-grade MK-2866 for in-vitro laboratory and research use only. View batch Certificates of Analysis → | Browse available research compounds → | Read: MK-2866 Mechanism of Action →